GlassScriptPhysician profile
Ronglin Li
NPI 1235518689
$3,551.58
in general payments reported to CMS, 2019-2025
29 companies · $936 in 2025
The $936 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $1,411 · 2023: $874 · 2024: $89.68 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $472.52 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $472.00 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $442.40 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.72 | 2021-2025 | Jardiance |
| Abbvie INC. | $236.98 | 2022 | |
| Novo Nordisk INC | $223.49 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.95 | 2023 | Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $122.53 | 2023-2025 | |
| Exact Sciences Corporation | $89.25 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $86.75 | 2025 | Voquezna |
| Dexcom, INC. | $75.10 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $72.87 | 2022-2025 | |
| Amgen INC. | $72.63 | 2024-2025 | Repatha, Evenity, Repatha |
| Medtronic, INC. | $65.49 | 2021-2023 | Intellis Adaptivestim |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $61.27 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $58.42 | 2021-2025 | Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $58.40 | 2023-2025 | |
| Dynavax Technologies Corporation | $50.32 | 2022-2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $46.39 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $33.80 | 2025 | Zoryve |
| Xeris Pharmaceuticals, INC. | $32.80 | 2022 | |
| Abbott Laboratories | $25.84 | 2022 | |
| Electromed, INC. | $21.86 | 2021 | |
| Daiichi Sankyo INC. | $21.15 | 2025 | Injectafer |
| Kyowa Kirin, INC. | $20.19 | 2025 | |
| Astellas Pharma US INC | $18.46 | 2025 | Veozah |
| Horizon Therapeutics Plc | $14.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronglin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.